Aerovate Therapeutics is committed to developing meaningful therapies to help people with rare cardiopulmonary diseases gain control over their disease.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $72.6M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | RA Capital... | racap.com |
| 06.08.2020 | Sofinnova ... | sofinnova.... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.08.2020 | Series A | $72.6M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.08.2020 | StartUPDATES: New developments from healthcare startups | Specifica has designed and created an exclusive antibody display library in collaboration with Scholar Rock. The collaborative library design will enable Scholar Rock to more easily and efficiently discover antibodies with characteristics c... |
| 07.08.2020 | Aerovate Therapeutics Inks $72.6M Series A | BOSTON, MA, Aerovate Therapeutics has closed on $72.6 million in Series A funding. >> Click here for more funding data on Aerovate Therapeutics >> To export Aerovate Therapeutics funding data to PDF and Excel, click here ... |
| 06.08.2020 | Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding | BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc., has closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension ... |
| - | StartUPDATES: New developments from healthcare startups | Specifica has designed and created an exclusive antibody display library in collaboration with Scholar Rock. The collaborative library design will enable Scholar Rock to more easily and efficiently discover antibodies with characteristics c... |